Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

• Prif Awduron: Ivelina Gueorguieva (Awdur), Ann Cleverly (Awdur), Durisala Desaiah (Awdur), Analia Azaro (Awdur), Joan Seoane (Awdur), Irene Braña (Awdur), Elisabet Sicart (Awdur), Colin Miles (Awdur), Michael M Lahn (Awdur), Malcolm I Mitchell (Awdur), Jordi Rodon (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: BioExcel Publishing Ltd, 2016-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...